Investors often track insider trading activity to anticipate a company’s future stock performance. For KalVista Pharmaceuticals Inc (NASDAQ: KALV), recent insider transactions have sparked interest as company executives adjusted their holdings amid steady analyst coverage.
On September 8, 2025, Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals Inc at $15.84 per share, totaling $115,537 in proceeds. Following the transaction, Palleiko’s holdings decreased to 395,189 shares, valued at approximately $4.3 million.
Additionally, Nicole Sweeny sold 1,480 shares at $13.42 per share, realizing over $19,862. After the sale, Sweeny now holds 32,291 shares in the company.
Earlier, Christopher Yea, the company’s Chief Development Officer, sold 1,954 shares for $13.42 each, generating $26,223. Following that trade, Yea’s holdings fell to 1,954 shares, estimated at around $1.44 million in value.
Analyst Coverage and Ratings for KalVista Pharmaceuticals Inc
Analysts remain largely positive on KalVista Pharmaceuticals (KALV). On January 31, 2025, JMP Securities reiterated its “Market Outperform” rating and set a price target of $19. Earlier, TD Cowen initiated coverage in early January with a “Buy” rating, while BofA Securities also launched coverage on December 18, 2024, maintaining a “Buy” stance.
In a longer historical context, H.C. Wainwright began coverage on June 15, 2020, and SVB Leerink initiated an “Outperform” rating on July 29, 2019, with a $31 price target, signaling strong long-term confidence in the company’s prospects.
Analyzing KALV Stock Performance
In the latest trading session, KalVista Pharmaceuticals Inc [NASDAQ: KALV] dipped -0.91% to close at $10.89. The stock fluctuated between $10.77 and $11.32 during the session. Over the last five days, KALV shares have dropped approximately -0.73%, and are down -6.36% year-to-date.
The stock’s 52-week range shows a high of $17.28 (September 11, 2025) and a low of $7.30 (January 13, 2025).
Support and Resistance Levels
Based on current trading patterns, support for KALV lies at $10.66, with a secondary level at $10.44 if the first is breached. Resistance levels are set at $11.22 and $11.55. The Relative Strength Index (RSI) stands at 39.97, reflecting neutral technical sentiment, suggesting that the stock may consolidate before a potential breakout.
Short Interest Trends
As of October 15, 2025, short interest in KalVista Pharmaceuticals Inc surged by 3.34 million shares, rising to 14.5 million from 11.16 million recorded on September 15, 2025—a 23.05% increase. This uptick indicates bearish sentiment among traders. Currently, shorted shares represent 10.68% of the total float, and the days-to-cover ratio climbed to 10.68, signaling elevated short positioning.
Institutional and Analyst Outlook
According to FactSet, analysts project an average 12-month price target of $20 for KalVista Pharmaceuticals Inc, implying an 81.98% upside from the recent closing price of $10.99. Some analysts forecast the stock could reach $28 by 2025, with the lowest price target at $20.
By the end of 2025, two analysts had rated KALV as a “Buy.” Long-term coverage from SVB Leerink, with its “Outperform” rating and $31 price target, further underscores institutional optimism around KalVista’s growth potential.
Overall, insider selling and rising short interest have introduced short-term pressure on KalVista Pharmaceuticals Inc (NASDAQ: KALV). However, consistent Buy ratings and substantial upside forecasts from analysts suggest that long-term investors may still view the stock as an opportunity for significant growth.